Despite intensive efforts, there are currently no disease-modifying treatments or preventive strategies for AD.

Jan 24, 2023 · Funded by the Marie Skłodowska-Curie Actions programme, the BBDiag project aims to address this limitation by identifying AD biomarkers and developing specific detection …

BBDiag responds to such a need and establishes a much-needed ETN for blood based early-AD diagnostics to address these challenges. It brings together leading academic and industrial …

BBDiag responds to such a need and establishes a much-needed ETN for blood based early-AD diagnostics to address these challenges. It brings together leading academic and industrial …

Jan 1, 2017 · BBDiag responds to such a need and establishes a much-needed ETN for blood based early-AD diagnostics to address these challenges. It brings together leading academic …

Blood Biomarker-based Diagnostic Tools for Early-stage Alzheimer鈥檚 Disease responds to challenges in early stage diagnosis of AD and timely sets up an ETN with the required …

During the Meeting, all early stage researchers and their mentors (see the Meeting Agenda in the following) presented main objectives, milestones, and deliverables of investigations planned in …

Jun 1, 2020 · Latest findings suggest EEG rhythms analysis as a valid screening tool to predict AD conversion. Alzheimer’s disease (AD) is the most common neurodegenerative disease …

During the Meeting, all early stage researchers and their mentors (see the Meeting Agenda in the following) presented main objectives, milestones, and deliverables of investigations planned in …

Cerebrospinal fluid (CSF) tests have the ability to identify earlier stages with the help of certain biomarkers but large scale use is often limited by invasive CSF collection protocols. This study …